1874276-76-2
1874276-76-2 structure
- Name: Darovasertib (LXS-196)
- Chemical Name: NVP-LXS196
- CAS Number: 1874276-76-2
- Molecular Formula: C22H23F3N8O
- Molecular Weight: 472.466
- Catalog: Signaling Pathways Epigenetics PKC
- Create Date: 2018-07-06 23:32:32
- Modify Date: 2024-01-09 17:47:39
-
LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under Phase I clinical trials for the treatment of uveal melanoma.
| Name | NVP-LXS196 |
|---|---|
| Synonyms |
2-Pyrazinecarboxamide, 3-amino-N-[3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl]-
3-Amino-N-[3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl]-2-pyrazinecarboxamide NVP-LXS196 LXS196 |
| Description | LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under Phase I clinical trials for the treatment of uveal melanoma. |
|---|---|
| Related Catalog | |
| Target |
PKC |
| In Vitro | Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 592.7±50.0 °C at 760 mmHg |
| Molecular Formula | C22H23F3N8O |
| Molecular Weight | 472.466 |
| Flash Point | 312.3±30.1 °C |
| Exact Mass | 472.194702 |
| LogP | 3.70 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.622 |
| Storage condition | 2-8℃ |